Kiniksa Pharmaceuticals International (KNSA) Expected to Announce Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is projected to post its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.37 per share and revenue of $200.8550 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International Stock Up 1.3%

Shares of NASDAQ:KNSA opened at $47.77 on Monday. The company has a market cap of $3.62 billion, a P/E ratio of 106.16 and a beta of 0.06. Kiniksa Pharmaceuticals International has a 52 week low of $18.25 and a 52 week high of $47.86. The business has a fifty day simple moving average of $42.72 and a 200-day simple moving average of $39.46.

Analysts Set New Price Targets

Several analysts have commented on KNSA shares. The Goldman Sachs Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday. They set a “buy” rating and a $62.00 price target for the company. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and an average target price of $53.71.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, December 8th. The shares were sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the transaction, the chief financial officer owned 31,086 shares in the company, valued at approximately $1,289,758.14. The trade was a 57.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Barry D. Quart sold 20,129 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $41.51, for a total transaction of $835,554.79. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $520,784.46. This trade represents a 61.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 123,823 shares of company stock valued at $5,244,967 over the last ninety days. Corporate insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth about $36,000. EverSource Wealth Advisors LLC lifted its position in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. CIBC Private Wealth Group LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. Quarry LP purchased a new position in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $44,000. Finally, Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.